Published in Br J Cancer on August 10, 2010
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. Int J Clin Oncol (2013) 0.86
Review of breast conservation therapy: then and now. ISRN Oncol (2011) 0.82
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. Radiol Oncol (2013) 0.81
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer (2014) 0.80
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. Br J Cancer (2015) 0.79
How can grafted breast cancer models be optimized? Cancer Biol Ther (2011) 0.78
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. BMC Cancer (2016) 0.75
Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. Front Oncol (2017) 0.75
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med (2005) 12.99
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst (2007) 4.46
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol (2001) 4.09
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol (2001) 3.44
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol (2007) 2.09
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res (2003) 2.04
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. J Clin Oncol (2005) 2.04
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed) (1982) 1.80
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol (2006) 1.62
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer (2007) 1.53
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat (2006) 1.51
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg (1991) 1.32
Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol (2003) 1.25
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol (2009) 1.14
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev (2006) 1.14
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat (2007) 0.97
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J (2001) 0.92
A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up. Crit Rev Oncol Hematol (2010) 0.91
Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer. Cancer Chemother Pharmacol (2008) 0.86
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer (2007) 0.84
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol (2001) 0.83
Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat (1995) 0.83
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol (2000) 1.72
Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem (2001) 1.51
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol (2012) 1.42
Conflict in an institutional setting: training and treatment considerations. J Adolesc (1980) 1.39
A multivalent pairing model of linkage analysis in autotetraploids. Genetics (2001) 1.21
Plasma corticotrophin releasing factor and vasopressin responses to exercise in normal man. Clin Endocrinol (Oxf) (1991) 0.97
The effects of alcoholism on the hypothalamic-pituitary-adrenal axis: interaction with endogenous opioid peptides. Clin Endocrinol (Oxf) (1995) 0.97
First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Br J Cancer (2004) 0.97
Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res (1999) 0.97
Characterization of phytoene synthase 1 gene (Psy1) located on common wheat chromosome 7A and development of a functional marker. Theor Appl Genet (2007) 0.96
The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat (1998) 0.94
Measurement of free-range activity in children as modified by social and environmental complexity. Am J Clin Nutr (1971) 0.92
Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. Am J Transplant (2013) 0.91
Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies. Pharmacogenomics J (2001) 0.91
The effect of acute exercise on the secretion of corticotropin-releasing factor, arginine vasopressin, and adrenocorticotropin as measured in pituitary venous blood from the horse. Endocrinology (1991) 0.90
Starch properties of mutant rice high in resistant starch. J Agric Food Chem (2006) 0.89
The utility of plasma CRH as a predictor of preterm delivery. J Clin Endocrinol Metab (2001) 0.87
The plasma ACTH, AVP, CRH and catecholamine responses to conventional and laparoscopic cholecystectomy. Clin Endocrinol (Oxf) (1993) 0.86
Definition and validation of operating equations for poly(vinyl alcohol)-poly(lactide-co-glycolide) microfiltration membrane-scaffold bioreactors. Biotechnol Bioeng (2010) 0.83
Trace element levels in the blood of workers in two steel works and a non-ferrous plant handling lead and cadmium compared with a non-exposed population. Sci Total Environ (1989) 0.83
Biological properties of chemically modified insulins. I. Biological activity of proinsulin and insulin modified at A1-glycine and B29-lysine. Diabetologia (1976) 0.81
A strategy to determine operating parameters in tissue engineering hollow fiber bioreactors. Biotechnol Bioeng (2011) 0.81
In vitro bioactivity of insulin analogues: lipogenic and anti-lipolytic potency and their interaction with the effect of native insulin. Diabetologia (1978) 0.80
Free insulin, C-peptide and glucagon profiles in insulin dependent diabetes mellitus. Aust N Z J Med (1980) 0.80
The acute effects of oral ethanol on the hypothalamic-pituitary-adrenal axis in normal human subjects. Clin Endocrinol (Oxf) (1995) 0.80
Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate? J Mammary Gland Biol Neoplasia (2000) 0.79
Reversal of hepatic encephalopathy and alteration in amino acid profiles after blocking a surgical splenorenal shunt by interventional radiological techniques. J Hepatol (1989) 0.79
Methylphenidate and the activity of hyperactives in the informal setting. Child Dev (1974) 0.79
Impact of age, phenotype and cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an adult population. Clin Endocrinol (Oxf) (2013) 0.78
Plasma corticotrophin releasing hormone, vasopressin, ACTH and cortisol responses to acute myocardial infarction. Clin Endocrinol (Oxf) (1994) 0.78
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines. J Med Chem (2000) 0.78
[Application of skin and soft tissue expansion in treatment of burn injury]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2000) 0.78
The RIIbeta regulatory subunit of protein kinase A binds to cAMP response element: an alternative cAMP signaling pathway. Proc Natl Acad Sci U S A (1998) 0.77
Two-dimensional crystals of reconstituted beta-subunits of the chaperonin TF55 from Sulfolobus shibatae. Biochim Biophys Acta (1998) 0.77
A comparison of the naloxone test with ovine CRH and insulin hypoglycaemia in the evaluation of the hypothalamic-pituitary-adrenal axis in normal man. Clin Endocrinol (Oxf) (1995) 0.76
Plasma cortisol, PRL, ACTH, AVP and corticotrophin releasing hormone responses to direct current cardioversion and electroconvulsive therapy. Clin Endocrinol (Oxf) (1996) 0.76
Biorhythms in the activity of children during free play. J Exp Anal Behav (1973) 0.75
Custody, treatment and the abnormal young male offender. Practitioner (1977) 0.75
Late coexistent acute cellular and antibody-mediated rejection in non-sensitized renal transplant patients. Int Urol Nephrol (2013) 0.75
[Changes in intra-articular pressure of the hip joint in Legg-Perthes disease]. Zhonghua Wai Ke Za Zhi (1984) 0.75
Delinquent drug takers: a follow up. J Adolesc (1979) 0.75
Proprioception variables as determinants of lapsed time estimation. Ergonomics (1968) 0.75
[Effects of flow-through descending branch of lateral circumflex femoral artery flap on repairing high-voltage electrical burn wounds of wrist of patients]. Zhonghua Shao Shang Za Zhi (2017) 0.75
Psychotherapy in Borstal. J Adolesc (1982) 0.75
A programmed cooling unit for experimental organ preservation. Cryobiology (1974) 0.75
The effect of beta-endorphin on basal and insulin-hypoglycaemia stimulated levels of hypothalamic-pituitary-adrenal axis hormones in normal human subjects. Clin Endocrinol (Oxf) (1996) 0.75
Regulation of corticotrophin secretion. Clin Sci (Lond) (1995) 0.75
Elevated basal adrenocorticotropin and evidence for increased central opioid tone in highly trained male athletes. J Clin Endocrinol Metab (1995) 0.75
Metyrapone induced increase in plasma corticotropin is not associated with changes in peripheral venous arginine vasopressin or corticotropin releasing factor. J Endocrinol Invest (1993) 0.75
Ovine proinsulin--identification and immunological similarity to bovine proinsulin. Aust J Exp Biol Med Sci (1974) 0.75
Proceedings: Pharmacodynamics of chemically modified insulins. J Endocrinol (1975) 0.75
Experimental study of early diagnosis and treatment of fat embolism syndrome. J Orthop Trauma (1995) 0.75
Doctors, prisoners and state - a conflict of interest? Midwife Health Visit Community Nurse (1980) 0.75
B1-3,5-diiodotyrosine insulin: a valid tracer for insulin. Diabetologia (1977) 0.75
[The effects of injection salviae miltiorrhizae in preventing and treating fat embolism syndrome]. Zhonghua Wai Ke Za Zhi (1994) 0.75
[Effects of flap or myocutaneous flap combined with fascia lata or composite mesh on repairing severe high-voltage electrical burn wounds in abdomen of patients]. Zhonghua Shao Shang Za Zhi (2017) 0.75
Atrial natriuretic peptide and C-type natriuretic peptide do not acutely inhibit the release of adrenocorticotropin from equine pituitary cells in vitro. Neuroendocrinology (1997) 0.75
Refining breast cancer risk assessment with molecular markers: the next step? J Natl Cancer Inst (1999) 0.75
Studies with the autotransplanted ovine pancreas: glucagon and insulin secretion. Aust J Biol Sci (1976) 0.75
[Reconstruction of perineal obliteration deformity after extensive deep burn with ilioinguinal flap]. Zhonghua Shao Shang Za Zhi (2016) 0.75
Can thyroid hormone mimics affect thyroid hormone measurement by immunoassay? Clin Biochem (2013) 0.75
Simultaneous radioimmunoassay of luteinizing hormone and follicle-stimulating hormone. J Endocrinol (1978) 0.75